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Summary
Background Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients 
with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant 
chemotherapy further improved survival compared with the current standard regimen.
Methods OE05 was an open-label, phase 3, randomised clinical trial. Patients with surgically resectable oesophageal 
adenocarcinoma classified as stage cT1N1, cT2N1, cT3N0/N1, or cT4N0/N1 were recruited from 72 UK hospitals. 
Eligibility criteria included WHO performance status 0 or 1, adequate respiratory, cardiac, and liver function, white 
blood cell count at least 3 × 10⁹ cells per L, platelet count at least 100 × 10⁹ platelets per L, and a glomerular filtration 
rate at least 60 mL/min. Participants were randomly allocated (1:1) using a computerised minimisation program with 
a random element and stratified by centre and tumour stage, to receive two cycles of cisplatin and fluorouracil (CF; 
two 3-weekly cycles of cisplatin [80 mg/m² intravenously on day 1] and fluorouracil [1 g/m² per day intravenously on 
days 1–4]) or four cycles of epirubicin, cisplatin, and capecitabine (ECX; four 3-weekly cycles of epirubicin [50 mg/m²] 
and cisplatin [60 mg/m²] intravenously on day 1, and capecitabine [1250 mg/m²] daily throughout the four cycles) 
before surgery, stratified according to centre and clinical disease stage. Neither patients nor study staff were masked 
to treatment allocation. Two-phase oesophagectomy with two-field (abdomen and thorax) lymphadenectomy was 
done within 4–6 weeks of completion of chemotherapy. The primary outcome measure was overall survival, and 
primary and safety analyses were done in the intention-to-treat population. This trial is registered with the ISRCTN 
registry (number 01852072) and ClinicalTrials.gov (NCT00041262), and is completed.
Findings Between Jan 13, 2005, and Oct 31, 2011, 897 patients were recruited and 451 were assigned to the CF group 
and 446 to the ECX group. By Nov 14, 2016, 327 (73%) of 451 patients in the CF group and 302 (68%) of 446 in the 
ECX group had died. Median survival was 23·4 months (95% CI 20·6–26·3) with CF and 26·1 months (22·5–29·7) 
with ECX (hazard ratio 0·90 (95% CI 0·77–1·05, p=0·19). No unexpected chemotherapy toxicity was seen, and 
neutropenia was the most commonly reported event (grade 3 or 4 neutropenia: 74 [17%] of 446 patients in the CF 
group vs 101 [23%] of 441 people in the ECX group). The proportions of patients with postoperative complications 
(224 [56%] of 398 people for whom data were available in the CF group and 233 [62%] of 374 in the ECX group; 
p=0·089) were similar between the two groups. One patient in the ECX group died of suspected treatment-related 
neutropenic sepsis.
Interpretation Four cycles of neoadjuvant ECX compared with two cycles of CF did not increase survival, and cannot 
be considered standard of care. Our study involved a large number of centres and detailed protocol with comprehensive 
prospective assessment of health-related quality of life in a patient population confined to people with adenocarcinomas 
of the oesophagus and gastro-oesophageal junction (Siewert types 1 and 2). Alternative chemotherapy regimens and 
neoadjuvant chemoradiation are being investigated to improve outcomes for patients with oesophageal carcinoma.
Funding Cancer Research UK and Medical Research Council Clinical Trials Unit at University College London.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Meta-analyses of randomised trials support the use of neo-
adjuvant chemotherapy or chemoradiotherapy before 
surgical resection of locally advanced oesophageal cancer to 
improve survival.1,2 Older clinical studies were dominated 
by squamous cell carcinoma3–12 but the increasing incidence 
of oesophageal adenocarcinoma, particularly in high-
income countries in the past 30 years, indicates a changing 
epidemiology. Most trials recruited patients with either 
squamous cell carcinoma or adenocarcinoma13–20 and 
although they were unable to show a survival difference 
between these two histological tumour types, none of the 
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studies were specifically powered to detect any such 
difference. Few studies have been done only in patients 
with oesophageal adenocarcinoma.21–24
High-quality data on the effect of neoadjuvant chemo-
therapy or chemoradiotherapy on health-related quality 
of life (HRQL) are scarce; more information is needed 
for clinical decision making, where small survival 
benefits might only be achieved with detrimental effects 
on many aspects of HRQL.
The results of the previous Medical Research Council 
(MRC) OE02 randomised clinical trial19 showed a 
survival advantage at 2 years with neoadjuvant chemo-
therapy and surgery over surgery alone (43% vs 34%; 9% 
increase [95% CI 3–14]), with a hazard ratio (HR) 
of 0·79 (95% CI 0·67–0·93), so two-cycle cisplatin with 
fluorouracil was used for the control group in this study. 
The randomised clinical MRC MAGIC trial25 assessed a 
regimen of three cycles of preoperative chemotherapy 
(epirubicin, cisplatin, and fluorouracil) followed by 
surgery and three postoperative cycles of chemotherapy 
in patients with gastric and oesophageal adeno-
carcinoma. The results showed a 5-year survival of 36% 
(95% CI 30–43) for perioperative chemotherapy and 
surgery compared with 23% (17–29) for surgery alone 
(overall survival HR 0·75, 95% CI 0·60–0·93).25 Because 
45% of participants in the MAGIC trial (34% of people 
who had surgery) did not receive postoperative 
treatment (a similar pattern was also seen in the 
FFCD-FNCLCC 9703 trial22), we concluded that further 
assessment of perioperative chemotherapy would be 
challenging and it was decided that increased 
neoadjuvant therapy would be the best strategy. Oral 
capecitabine is readily available and has been shown to 
be equivalent to intravenous fluorouracil in colorectal 
cancer,26 so we decided to investigate four cycles of 
neoadjuvant epirubicin, cisplatin, and capecitabine 
(ECX) as the investigational group without postoperative 
chemotherapy. Given the results of the MAGIC trial, 
increasing the duration of neoadjuvant chemotherapy 
from two cycles to four cycles and adding anthracycline 
to the established doublet regimen was considered the 
most promising strategy for improving outcomes in 
patients with oesophageal adenocarcinoma in this 
study. A regimen of four cycles of ECX was selected 
because in studies of patients with advanced disease, up 
to 50% of patients develop resistant disease after 
24 weeks of treatment and most responses have 
occurred by four cycles.27
The aims of the OE05 trial were therefore to investigate 
whether four cycles of preoperative ECX improves 
survival and HRQL compared with standard two-cycle 
cisplatin and fluorouracil (CF) in patients with locally 
advanced resectable adenocarcinoma of the oesophagus.
Methods
Study design and participants
The UK MRC OE05 study is an open-label, phase 3, 
randomised clinical trial done in 72 hospitals across the 
UK. Participants were of any age with surgically resectable 
histologically verified adenocarcinoma of the oesophagus 
(including Siewert types 1 and 2 gastro-oesophageal 
junction tumours) stage cT1N1, cT2N1, cT3N0/N1, or 
cT4N0/N1 where invasion was thought to be confined to 
diaphragm, crura, or mediastinal pleura and surgically 
resectable (Union for International Cancer Control 
[UICC] TNM staging28). Additionally, patients had to meet 
the following criteria: WHO performance status 0 or 1 
and adequate respiratory and cardiac function (forced 
expiratory volume in 1 sec of >1·5 L and cardiac ejection 
fraction of ≥50% on echocardiography or multigated 
acquisition scan) within 4 weeks of randomisation. 
Within 1 week of randomisation, liver function tests 
needed to be at most 1·5-times normal, white blood cell 
count at least 3 × 10⁹ cells per L, platelet counts at least 
100 × 10⁹ platelets per L, and the calculated or measured 
glomerular filtration rate at least 60 mL/min.
Research in context
Evidence before this study
On Jan 12 and 13, 2017, we searched PubMed and the abstracts 
of major conferences such as the American Society of Clinical 
Oncology for publications in English, with no publication date 
restrictions. The search terms used were “chemotherapy”, “neo-
adjuvant (or neoadjuvant)”, and “oesophageal (or esophageal)”. 
We identified two meta-analyses comparing neoadjuvant 
chemotherapy with surgery alone in patients with oesophageal 
cancer. These meta-analyses showed a significant survival 
benefit after treatment with neoadjuvant chemotherapy, both 
overall and for the subset of patients with adenocarcinoma who 
were considered in this study. These meta-analyses were unable 
to assess the benefits of different neoadjuvant chemotherapy 
regimens, and we can identify no phase 3 randomised trials that 
have directly compared different regimens.
Added value of this study
To our knowledge, this is the largest randomised trial 
investigating whether an alternative neoadjuvant 
chemotherapy regimen might offer a survival benefit over the 
standard of two cycles of cisplatin and fluorouracil (CF). This 
trial showed that giving four cycles of epirubicin, cisplatin, and 
capecitabine (ECX) neoadjuvantly might increase the level of 
tumour regression, but does not lead to any survival benefit.
Implications of all available evidence
For patients with oesophageal adenocarcinoma, two cycles of 
CF should remain the standard choice of neoadjuvant 
chemotherapy regimen. Further research is ongoing into the 
use of neoadjuvant chemoradiotherapy, but little evidence 
exists that directly compares it to neoadjuvant chemotherapy.
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Assessment of disease stage required a contrast-
enhanced multislice CT scan from neck to pelvis and 
endo scopic ultrasonography within 4 weeks of 
randomisation. Staging laparoscopy with or without 
peritoneal cytology and PET scanning were optional 
according to local practice. The final staging of patients 
(and Siewert classification) was done on the basis of a 
multidisciplinary team discussion following endoscopy, 
endoscopic ultrasonography, CT, and laparoscopy if 
appropriate.
Patients were ineligible if investigations indicated 
blood-borne metastases (radiologically assessed), 
peritoneal dissemination, local invasion involving the 
tracheobronchial tree, aorta, pericardium or lung, or 
abdominal para-aortic lymphadenopathy greater than 
1 cm in diameter on CT scan or more than 6 mm in 
diameter on endoscopic ultrasonography. Patients were 
also excluded if they had received any previous treatment 
for oesophageal cancer, had Siewert type 3 cancer, a 
medical condition that was likely to compromise the 
proposed trial treatment. Uncontrolled angina pectoris, 
myocardial infarction in the 6 months before entry into 
the trial, heart failure, clinically significant uncontrolled 
cardiac arrhythmias, or any patient with a clinically 
significant abnormal ECG, as well as patients with 
abnormal left ventricular ejection fraction (LVEF) 
diagnosed on MUGA scan or echocardiography, 
including areas of abnormal contractility, were excluded. 
Patients with positive serology for HIV or hepatitis C, 
active hepatitis B, or were pregnant were also excluded.
 Participating centres were considered eligible if they had 
a multidisciplinary team structure, had experience of two-
phase oesophagectomy with two-field lymphadenectomy 
(unproctored surgeons were recommended to have done a 
minimum of 12 such operations before joining the trial), 
access to multislice CT and endoscopic ultrasonography 
equipment, and had pathologists who were experienced in 
reporting oesophageal cancer.
The protocol was approved by the South West Multicentre 
Research Ethics Committee (04/6/005) and all patients 
gave written consent for participation in the study. Blood 
and tissue samples were collected for potential future 
translational studies (Trans-OE05). The protocol had five 
amendments during the course of the trial, predominantly 
for administrative reasons or to add clarity; amendments 
did not affect the eligibility or treatment of patients. The 
most recent version of the protocol (version 6.0) is available 
online.
Randomisation and masking
Eligible patients were enrolled by staff at participating 
centres who then called the randomisation line at the MRC 
Clinical Trials Unit at UCL (London, UK). Patients were 
randomly assigned (1:1) to either two cycles of CF or four 
cycles of ECX. Allocation was done using a computerised 
minimisation program, with a random element, and 
stratified by centre and tumour stage. No masking to 
treatment allocation was done because of the difference in 
the number of chemotherapy cycles in the two groups.
Procedures
The control group chemotherapy regimen was 
two 3-weekly cycles of cisplatin and fluorouracil. Cisplatin 
(80 mg/m²) was infused intravenously on day 1 and 
fluorouracil (1 g/m² per day) was administered intra-
venously on days 1–4 (total 4 g/m²).
The investigational chemotherapy was four 3-weekly 
cycles of ECX. Epirubicin (50 mg/m²) and cisplatin 
(60 mg/m²) were given intravenously on day 1 and 
capecitabine (1250 mg/m² daily) was given orally 
continuously over all four cycles (for a total of 12 weeks).
Protocols for chemotherapy dose modifications were 
provided for haematological, renal, neurological, and 
hepatic toxicities, and for palmar–plantar erythema, 
stomatitis, diarrhoea, nausea, and vomiting. Toxicities 
were reported according to the National Cancer Institute 
Common Toxicity Criteria, version 3.0.29
Surgery was done within 4–6 weeks of completion of 
chemotherapy. Surgery was a two-phase oesophagectomy 
with a two-field (abdomen and thorax) lymphadenectomy. 
Centres were allowed to use a minimal access surgery 
approach after providing evidence that complication 
rates and lymph node yields were similar to an open 
surgery approach from at least 20 patients who had had 
minimal access oesophagectomy.
The stomach was the preferred conduit for recon-
struction based on the right gastric and right gastroepiploic 
vessels. Lymph node clearance in the abdomen was at the 
origin of the left gastric artery and along the hepatic and 
splenic arteries, the upper lesser curve, and at the right 
and left cardiac lymph node stations. Dissection at the 
diaphragm was used to minimise a positive radial or 
circumferential resection margin by inclusion of sufficient 
crural fibres and a cuff of diaphragm based on endoscopic 
ultrasonography and intraoperative appearances. Pyloro-
plasty, pyloromyotomy, the placement of a feeding 
jejunostomy, and drain insertions were all according to 
local practice.
Either a right or left thoracic approach was permitted. 
Lymph node dissection involved para-oesophageal, 
subcarinal, and bronchial lymph node stations, and 
thoracic duct ligation just above the diaphragm was 
advised. The extent of proximal lymphadenectomy for 
the upper paraoesophageal nodes was determined by the 
extent of division of the oesophagus (ie, the length of 
oesophagus remaining after resection).
Reconstruction was recommended above the aortic 
arch for the right-sided approach and just below it for the 
left, and preferably within 5 cm of the thoracic inlet. The 
anastomotic technique and method of chest drainage 
was according to local practice. Trans-hiatal surgery was 
not permitted.
Postoperative complications, described as none, 
present but not life threatening, or life threatening, were 
For the OE05 Clinical Trial 
Protocol Version 6.0 see 
http://www.ctu.mrc.ac.uk/
research/documents/cancer_
protocols/OE05_Protocol_
Version_6_23_Dec_09.pdf
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recorded for each patient. These complications were 
reviewed clinically, and assigned to categories.
Processing of the surgical resection specimens and 
histopathological assessment of all materials were done 
according to the recommendations of the Royal College of 
Pathologists:30 R0, no tumour cells remaining within 
1 mm of any resection margin; R1, microscopically visible 
positive margin indicating the presence of tumour cells 
at or within 1 mm of a longitudinal or radial or 
circumferential resection margin; and R2, macroscopically 
visible tumour remaining. Resection specimens were 
classified using UICC TNM, 6th edition.28 Chemotherapy-
induced changes in the primary tumour were graded 
according to Mandard and colleagues.31 The Mandard 
tumour regression grading (TRG) system was developed 
originally for the assessment of squamous cell carcinoma 
after chemoradiation, and was used in this study because 
UK pathologists are familiar with this system and it has 
been shown to be equivalent to the Becker grading system 
in terms of both interobserver agreement (ie, likelihood 
of two pathologists concluding the same grading by their 
independent assessments) and prognostic ability.32,33
Pathology data were collected from local pathologists at 
each centre, and used for the primary analyses of all 
pathology data. A second review of the Mandard primary 
TRG was done to assess data quality and the differences 
between local and central assessments of TRG. One of 
three experienced pathologists (HIG, RL, and SP) 
independently reviewed all resection slides and provided 
a new Mandard TRG. If the reviewing pathologist’s TRG 
agreed with the local pathologist assessment, this TRG 
was accepted as the true grade. If the reviewing 
pathologist disagreed, a second, and if necessary a third, 
pathologist reviewed the slides to reach a majority 
decision on the Mandard TRG. These centrally reviewed 
data form a secondary analysis of TRG.
All participating patients were asked to complete 
the validated generic cancer questionnaire (European 
Organisation for Research and Treatment of Cancer 
[EORTC] QLQ-C30)34 and the disease-specific oesophageal 
module (EORTC QLQ-OES18)35 at baseline, day 14 of 
chemotherapy cycle two, day 14 of cycle four (ECX group 
only), immediately before surgery, at 6 weeks, at 3, 6, 9, 
12, 18, and 24 months after surgery, then annually. 
Patients could complete questionnaires at home and 
bring them to the hospital, return them by post, or 
complete them at their clinical follow-up visit. The HRQL 
protocol prespecified four domains of HRQL to be 
examined in the primary analyses and full details of all 
scales and items assessed in the questionnaires will be 
reported subsequently. Clinical follow-up involved the 
same schedule with the use of tests to establish recurrent 
disease at the discretion of individual centres.
Outcomes
The primary outcome measure of the trial was overall 
survival. Secondary outcomes were disease-free survival, 
effects on the primary tumour (as assessed by Mandard 
TRG), HRQL, and morbidity related to chemotherapy 
and surgery. Exploratory outcomes were progression-free 
survival (where a progression-free survival event was 
defined as the first confirmed local or distant recurrence, 
or death from any cause), and an analysis of Mandard 
TRG using an amended responder definition.
Statistical analysis
The sample size calculations were based on the primary 
outcome measure of overall survival. On the basis of the 
OE02 trial results,19 which showed an absolute survival 
difference of 8% at 3 years, we thought it unlikely that 
any greater difference would be seen in this study. The 
trial was originally designed to require 1300 patients and 
860 events, with recruitment over 6 years and a 
minimum follow-up period of 6 months. With a 
5% two-sided significance level, this sample would 
provide 90% power to detect an 8% difference (or 
Figure 1: Consort diagram
CF=cisplatin and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine. *Cause of death reported as cardiac 
failure. †Causes of death reported as cerebral vascular accident, multiple organ failure, pulmonary embolism, 
bronchopneumonia, and oesophageal cancer. ‡For patients not listed in † above, cause of death was reported as 
sepsis-related multiple organ failure in one patient and oesophageal cancer in the remaining two patients. 
Screening logs were not collected during the trial, so the number of potentially eligible patients is unknown. 
16 received less than two cycles 
 of chemotherapy
 8 toxicity
 4 patient choice
 3 change in condition or 
 progression
 1 patient died*
83 received less than four cycles 
 of chemotherapy
 46 toxicity
 10 patient choice 
 19 change in condition or 
 progression
 5 patients died†
 1 other, not trial related
 2 unknown
435 received full two cycles of chemotherapy 363 received full four cycles of chemotherapy
40 did not have surgery
 20 disease progression
 17 comorbidities or 
       otherwise inoperable
 2 patient choice
 1 patient died*
59 did not have surgery
 21 disease progression
 23 comorbidities or 
       otherwise inoperable 
 7 patient choice
 8 patients died‡
411 had surgery
 24 did not have resection
 387 did have resection
387 had surgery
 23 did not have resection
 364 did have resection
451 included in the intention-to-treat 
 analyses
446 included in the intention-to-treat 
 analyses
897 randomly assigned
451 allocated to CF 446 allocated to ECX
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80% power to detect a 7% difference) in 3-year survival, 
from 30% in the CF group. In 2007, following a period of 
lower than expected recruitment, the sample size was 
reassessed to ensure that an adequately powered study 
would still be achieved in a given timeframe. The 
updated sample size calculations required 842 patients 
with 677 events over 6 years with a minimum follow-up 
of 2 years before analysis, to provide at least 82% power 
to detect an 8% difference (and 70% to detect a 
7% difference) at 3 years with a two-sided significance 
level of 5%.
Although we anticipated that the required events would 
be obtained 2 years after the final patient was randomly 
assigned, they accrued far more slowly than expected. 
3 years after the final randomisation, a conditional 
survival analysis was done to assess the probability that 
continuing to wait for the full number of events would 
lead to a different trial conclusion. After discussion with 
the independent data monitoring committee and trial 
steering committee, a decision was reached that the 
current data were sufficiently robust for full analysis and 
dissemination, because the chance of obtaining a 
different conclusion with more events was less than 5%.
All safety and primary analyses were done on an 
intention-to-treat basis. Overall survival was calculated 
from the date of group assignment to the date of death. 
Patients either lost to follow-up or still alive at the time of 
analysis were censored at the date they were last known 
to be alive.
Because patients can only be deemed disease free after 
surgery, and to account for the different durations of 
preoperative chemotherapy, disease-free survival was 
analysed using a landmark analysis.36 Rather than the date 
of randomisation, the time 1 week after the last patient had 
surgery was used as the start point, up to a maximum of 
6 months from group assignment. Patients who had an 
event before this point, who did not have surgery, or who 
were not macroscopically disease free at surgery, were said 
to have had an event on day 1. If any patients received 
surgery more than 6 months after randomisation, they 
were assumed to be disease free at the 6-month start point. 
Disease-free survival was calculated as the time from this 
modified origin until the first date of confirmed local 
recurrence, distant metastases, or death from any cause. 
Patients who had no evidence of relapse were censored on 
the last date they were known to be disease free.
 Progression-free survival was calculated from random 
assignment to the date of the event or, in event-free 
patients, the date last known to be alive and free from 
recurrence. Overall, disease-free, and progression-free 
survival were compared using the log-rank χ² test. The 
proportion of patients who survived and median survival 
times were estimated from a flexible parametric survival 
model37 and presented with 95% CIs. HRs were calculated 
from Cox proportional hazard models, including 
adjustment for randomisation stratification factors. 
Proportional hazards assumptions were tested using the 
Grambsch-Therneau test. The heterogeneity of treatment 
effects across levels of prespecified patient characteristics 
(sex, age, performance status, clinical T-stage, and 
clinical N-stage) were explored using Cox proportional 
hazard models.
To analyse tumour regression, the original five-point 
Mandard scale was dichotomised into responders 
(Mandard TRG 1–3) and non-responders (Mandard 
TRG 4–5). A second, unplanned analysis was also done 
because emerging evidence suggested that a more 
appropriate dichotomisation was Mandard TRG 1–2 as 
responders and grades 3–5 as non-responders.
Formal comparisons and summaries of HRQL 
function and symptom scales were restricted to a number 
of prespecified outcome measures. Global HRQL and 
prespecified symptoms related to the effects of 
chemotherapy and surgery (appetite loss, dysphagia, 
pain, and reflux) were compared immediately before 
surgery, and 3, 12, and 24 months after surgery, using an 
ANOVA with adjustment for baseline score. These 
timepoints were considered separately, rather than using 
a repeated measures method of analysis.
Comparisons between chemotherapy toxicities, 
surgical complications, tumour regression, and resection 
were done using a χ² test or Fisher’s exact test, as 
appropriate. A p value of less than 0·05 was used as the 
Cisplatin 
and fluorouracil 
(n=451)
Epirubicin, cisplatin, 
and capecitabine 
(n=446)
Sex
Female 39 (9%) 48 (11%)
Male 412 (91%) 398 (89%)
Age, years
Median (IQR) 62 (57–67) 62 (56–67)
Range 27–81 33–80
WHO performance status
0 311 (69%) 292 (65%)
1 140 (31%) 154 (35%)
Stage of tumour*
T1 N1 3 (1%) 5 (1%)
T2 N1 49 (11%) 41 (9%)
T3 N0 97 (22%) 99 (22%)
T3 N1 287 (64%) 289 (65%)
T4 N0† 3 (1%) 1 (<1%)
T4 N1† 12 (3%) 11 (2%)
Participating in quality-of-life assessment
Yes 435 (96%) 424 (95%)
No 16 (4%) 22 (5%)
Data are n (%) unless otherwise specified. *Stage of tumour (based on both 
endoscopic ultrasonography and CT results) was used to stratify randomisation. 
†Specific site of T4 invasion is mediastinal pleura for eight patients (four in the 
cisplatin and fluorouracil group vs four in the epirubicin, cisplatin, and 
capecitabine group), crura for 14 patients (nine vs five), and diaphragm for 
five patients (two vs three).
Table 1: Baseline characteristics
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significance threshold. For all analyses, no attempts were 
made to impute values for missing data. All analyses 
were done using Stata, version 14.
This trial is registered with the ISRCTN registry 
(registration number 01852072) and ClinicalTrials.gov 
(NCT00041262).
Role of the funding source
Cancer Research UK approved the study design, but had 
no role in data collection, data analysis, data 
interpretation, or writing of the report. Roche supplied 
capecitabine for use in the study, and had sight of the 
draft trial manuscript, but had no role in any other aspect 
of the study. MN had access to the raw data. The 
corresponding author had final responsibility for the 
decision to submit for publication.
Results 
Between Jan 13, 2005, and Oct 31, 2011, 897 patients were 
recruited from 72 UK hospitals and randomly allocated 
to the CF group (n=451) or the ECX group (n=446; 
figure 1). The median number of patients per centre 
was eight (range 1–73; appendix pp 1–3). After 
chemotherapy, following retrospective review of the 
baseline CT scan, one patient was found to be ineligible 
because of adrenal metastases so did not have surgery, 
but was included in all summaries and analyses. The 
baseline characteristics of the patients allocated to the CF 
or ECX groups were similar (table 1). The median age 
was 62 years (IQR 56–67; range 27–81), 810 (90%) of 
897 patients were male, 603 (67%) had a WHO 
performance status of 0, and 576 (64%) had stage T3N1 
cancer (table 1; appendix pp 4–5).
Three (4%) of 72 recruiting centres did not take part in 
the HRQL aspect of the trial for any of their patients, and 
HRQL assessment data were omitted at baseline for the 
patients from these centres (37 [4%] of the total 
897 patients). Baseline HRQL was also well balanced 
Cisplatin and 
fluorouracil: 
two cycles 
(n=451)
Epirubicin, 
cisplatin, 
and capecitabine: 
four cycles (n=446)
Cycles started
None* 2 (<1%) 2 (<1%)
One 14 (3%) 12 (3%)
Two (completed two-cycle 
regimen)
435 (96%) 32 (7%)
Three NA 37 (8%)
Four (completed four-cycle 
regimen)
NA 363 (81%)
Total completed chemotherapy 435 (96%) 363 (81%)
Delays to cycles†
Yes 113 (25%) 148 (33%)
No 336 (75%) 296 (66%)
No chemotherapy received 2 (<1%) 2 (<1%)
Reduction in cisplatin dose‡
No 373 (83%) 378 (85%)
Yes 61 (14%) 53 (12%)
No cisplatin given 1 (<1%) 1 (<1%)
Less than two cycles given 16 (4%) 14 (3%)
Reduction in any dose‡
No 347 (77%) 245 (55%)
Yes 88 (20%) 187 (42%)
Less than two cycles given 16 (4%) 14 (3%)
Data are n (%). NA=not applicable. *All four patients who received no on-trial 
chemotherapy withdrew consent soon after randomisation. †A delay is defined as 
a cycle starting at least 25 days after the previous cycle, or at least 11 days after 
randomisation. ‡A reduction is defined as the dose decreasing by more than 10% 
compared with cycle one. A cycle was said to have started if any drug was 
administered.
Table 2: Chemotherapy details
Cisplatin and 
fluorouracil 
(n=451)
Epirubicin, 
cisplatin, 
and capecitabine 
(n=446)
Surgery done
Yes 411 (91%) 387 (87%)
No 40 (9%) 59 (13%)
Reason for no surgery*
CT evidence of disease progression 13 (33%) 11 (19%)
Clinical evidence of disease 
progression
3 (8%) 6 (10%)
Laparoscopic evidence of disease 
progression
4 (10%) 4 (7%)
Comorbidity 6 (15%) 9 (15%)
Patient choice 2 (5%) 7 (12%)
Patient died 1 (3%) 8 (14%)
Patient otherwise deemed inoperable 11 (28%) 14 (24%)
Resection done
Yes 387 (86%) 364 (82%)
No (open-close operation) 24 (5%) 23 (5%)
Surgical approach†
Abdomen and right chest open 192 (50%) 187 (51%)
Abdomen (laparoscopic) 
and right chest open
108 (28%) 101 (28%)
Left thoracoabdominal incision 28 (7%) 24 (7%)
Totally laparoscopic 9 (2%) 9 (2%)
Other 43 (11%) 35 (10%)
Missing 7 (2%) 8 (2%)
Location†
Mid-oesophagus 72 (19%) 56 (15%)
Siewert type 1 227 (59%) 208 (57%)
Siewert type 2 76 (20%) 89 (24%)
Missing 12 (3%) 11 (3%)
Data are n (%). An open-close operation was deemed as one in which no resection 
was done, or the reason given on the case report form for not having surgery was 
that the patient was found to be inoperable at laparotomy or thoracotomy. 
*Percentages are out of patients who did not have surgery. †Percentages are out 
of all patients who did have resection.
Table 3: Surgery details
See Online for appendix
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between the two groups. Mean values (SD) for the 
five prespecified domains of interest were: global HRQL 
76·0 (18·34), appetite loss 37·4 (27·98), reflux 
17·3 (24·05), pain 20·3 (20·50), and dysphagia 
73·9 (25·7); data per treatment group are in the appendix 
(pp 8–10). A higher score indicates better HRQL for the 
global score and dysphagia, but worse HRQL for the 
symptom scales.
Details of the chemotherapy received are shown in 
table 2. Four patients (<1%; two in the CF group and two 
in the ECX group) of 897 withdrew consent before 
starting chemotherapy and five (1%; one CF, four ECX) 
died during chemotherapy. The number of patients 
who completed their allocated treatment was greater 
in the CF group than in the ECX group (435 [96%] 
of 451 vs 363 [81%] of 446; p<0·0001), although a similar 
number of patients in the CF (435 [96%] of 451) and ECX 
(432 [97%] of 446) groups received at least two cycles. Of 
the 451 patients in the CF group, eight (2%) stopped 
chemotherapy because of toxicity and one (<1%) died, 
whereas in the ECX group, 46 (10%) of 446 patients 
stopped because of toxicity, and five (1%) died, one of 
which was thought to be related to chemotherapy toxicity 
(figure 1). The number of patients requiring dose 
reduction to any drug was smaller in the CF than in 
the ECX group (88 [20%] of 451 vs 187 [42%] of 446; 
p<0·0001), although the number receiving cisplatin dose 
reductions was similar between the groups (61 [14%] 
of 451 in the CF group and 53 [12%] of 446 in the 
ECX group).
The median time from randomisation to surgery was 
71 days (IQR 66–80) in the CF group and 127 days 
(119–137) in the ECX group. The median time of surgery 
from the start of the last preoperative chemotherapy 
cycle was 44 days (39–52) for patients in the CF group 
and 57 days (52–64) for patients in the ECX group. Details 
of the surgical procedure are shown in table 3. Of the 
897 patients who were enrolled, 99 (11%) did not have 
surgery. Of the 99 who did not have surgery, 41 (41%) 
were because of disease progression, nine (9%) died 
before surgery, nine (9%) decided not to have surgery, 
15 (15%) developed significant comorbidities that 
precluded surgery, and 25 (25%) were deemed otherwise 
unsuitable for surgery. In total, 411 (91%) of 451 patients 
in the CF group and 387 (87%) of 446 patients in the ECX 
group proceeded to surgery (figure 1).
751 (84%) of 897 people had resection and 
reconstruction, whereas 47 (5%) of 897 patients were 
found to have progressive disease or to be inoperable 
during surgery (table 3). 588 (78%) of 751 resections were 
done via the abdomen and right chest using open surgery 
throughout (Ivor-Lewis resection) or as hybrid with a 
laparoscopic abdominal approach. Only 18 (2%) of the 
751 resections (nine in each group) were done with a 
totally minimally invasive approach.
As of Nov 14, 2016, 629 (70%) of 897 patients were 
known to have died (327 [73%] of 451 in the CF group and 
302 [68%] of 446 in the ECX group) and a further 12 had 
withdrawn consent for further follow-up. The median 
follow-up of the surviving patients was 6·4 years 
(IQR 4·8–8·2), and 250 (93%) of 268 patients had at least 
3 years of follow-up assessments. The observed 3-year 
overall survival was 39% (95% CI 35–44) in the CF group, 
and 42% (37–47) in the ECX group (figure 2). Median 
overall survival was estimated to be 23·4 months (95% CI 
20·6–26·3) in the CF group and 26·1 months (22·5–29·7) 
in the ECX group, with an HR of 0·90 (95% CI 0·77–1·05, 
p=0·19). No evidence indicated that the proportional 
hazards assumption was violated.
Figure 3 shows prespecified subgroup analyses of 
overall survival were done, considering sex, age group 
(<60 years, 60–69 years, and ≥70 years), WHO 
performance status, clinical T-stage, and clinical N-stage 
(appendix p 11).
Median disease-free survival (347 events in the 
CF group vs 316 events in the ECX group, based on a 
6-month landmark analysis; appendix p 13) was 
11·6 months (95% CI 8·9–13·3) in the CF group and 
14·4 months (11·7–16·5) in the ECX group, with an 
HR of 0·86 (95% CI 0·74–1·00, p=0·051).
Chemotherapy toxicity data were not provided by three 
patients in each group and two in each group did not 
receive any chemotherapy. Grade 3 or 4 diarrhoea 
occurred in six (1%) of 446 people in the CF group and 
36 (8%) of 441 in the ECX group (p<0·0001) and grade 3 
or 4 neutropenia occurred in 74 (17%) of 446 in the CF 
group and 101 (23%) of 441 people in the ECX group 
(p=0·023); stomatitis occurred in 25 (6%) of 446 people 
in the CF group versus seven (2%) of 441 in the ECX 
group (p=0·0018; table 4 and appendix p 6).
More patients in the ECX group (108 [24%] of 446) 
reported serious adverse events over the course of the 
trial than in the CF group (73 [16% of 451], p=0·003; 
appendix p 7). Particularly, reports of diarrhoea were 
more common in the ECX group (14 [3%]) than in the CF 
Figure 2: Overall survival
CF=cisplatin and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine.
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group (0, p<0·0001). No significant differences were 
measured between the groups for any other type of event, 
or in any specific body systems (appendix p 7). 
In patients for whom data were reported, no 
difference was seen in the overall prevalence of surgical 
complications between the two treatment groups 
(224 [56%] of 398 people in the CF group and 233 [62%] 
of 374 in the ECX group; p=0·089), although more 
people in the ECX group had respiratory complications 
(125 [33%] of 374) than in the CF group (107 [27%] 
of 398; p=0·048; appendix p 7). At 30 days after surgery, 
ten (2%) of 411 patients in the CF group and 11 (3%) of 
387 people in the ECX group had died, and at 90 days, 
21 (5%) people in the CF group and 23 (6%) people in 
the ECX group had died.
In the local pathologist review (table 5), the primary 
tumour was classified as Mandard TRG 1–3 in 44 (15%) of 
the 288 specimens with available results from the CF 
group and 93 (32%) of the 289 specimens from the ECX 
group (p<0·0001). Mandard primary tumour regression 
data were also available from central pathology review of 
656 patients (87% of patients who had a resection) and a 
total of 24 625 slides were received, with a median of 
34 (IQR 24–45) slides per person. Similar incidences of 
tumour regression were seen with 91 (29%) of 
317 specimens graded as TRG 1, 2, or 3 in the ECX group 
and 40 (12%) of 339 in the CF group (p<0·0001).
More specimens from the ECX group were classified 
by the local pathologist as ypT0 or T1 (34 [9%] of 383 CF 
vs 68 [19%] of 359 ECX; p<0·0001) after surgery and the 
number of patients categorised as ypN0 was also higher 
after ECX (115 [30%] of 385 CF vs 142 [39%] of 361 ECX; 
Figure 3: Subgroup analysis
Data are number of patients who had a survival event (n) out of the total number of patients (N), or HR (95% CI). The subgroup of patients with T1 disease at 
randomisation is not shown because there were only three patients who had CF and five who had ECX treatment. p values for heterogeneity of treatment effect are 
0·69 for sex, 0·05 for age, 0·46 for WHO performance status, 0·11 for T-stage, and 0·028 for N-stage. T-stage and N-stage refer to clinical staging collected at time of 
randomisation. CF=cisplatin and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine.
Sex
Age group
WHO performance status
T-stage
N-stage
Overall
Male
Female
<60 years
60–69 years
≥70 years
0
1
T2
T3
T4
N0
N1
All patients
304/412
 23/39
113/171
162/212
 52/68
215/311
112/140
 34/47
277/386
 13/15
 71/97
255/350
327/451
CF (n/N)
275/398
 27/48
120/172
119/192
 63/82
190/292
112/154
 25/40
266/389
 8/12
 55/97
243/345
302/446
ECX (n/N)
0·89 (0·76–1·05)
0·98 (0·56–1·72)
1·06 (0·82–1·37)
0·72 (0·57–0·91)
1·09 (0·76–1·58)
0·92 (0·76–1·12)
0·82 (0·63–1·07)
0·84 (0·50–1·41)
0·93 (0·79–1·10)
0·51 (0·21–1·24)
0·63 (0·45–0·90)
0·97 (0·81–1·16)
0·90 (0·77–1·05)
HR (95% CI)
0·6 0·8 1·0 1·2 1·4
Favours ECX Favours CF
p value
0·18
0·95
0·67
0·0061
0·48
0·39
0·15
0·011
0·73
0·51
0·39
0·13
0·17
Cisplatin and fluorouracil: 
two cycles (n=446*)
Epirubicin, cisplatin, 
and capecitabine: four cycles 
(n=441*)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Neutropenia 102 (23%) 57 (13%) 17 (4%) 119 (27%) 79 (18%) 22 (5%)
Deep vein thrombosis or 
pulmonary embolism
5 (1%) 4 (1%) 5 (1%) 11 (2%) 8 (2%) 11 (2%)
Vomiting 116 (26%) 20 (4%) 0 177 (40%) 26 (6%) 0
Nausea 245 (55%) 16 (4%) 0 282 (64%) 27 (6%) 0
Diarrhoea 103 (23%) 6 (1%) 0 132 (30%) 33 (7%) 3 (1%)
Plantar–palmar 
erythrodysesthesia
27 (6%) 0 0 169 (38%) 37 (8%) 1 (<1%)
Stomatitis 212 (48%) 25 (6%) 0 199 (45%) 7 (2%) 0
Infection or febrile 
neutropenia
5 (1%) 2 (<1%) 1 (<1%) 6 (1%) 14 (3%) 0
Cardiac toxicity 13 (3%) 1 (<1%) 1 (<1%) 17 (4%) 2 (<1%) 1 (<1%)
Peripheral neuropathy 27 (6%) 1 (<1%) 0 103 (23%) 3 (1%) 0
Loss of taste 147 (33%) 2 (<1%) 0 180 (41%) 1 (<1%) 0
Thrombocytopenia 28 (6%) 2 (<1%) 0 32 (7%) 0 1 (<1%)
Renal toxicity 28 (6%) 2 (<1%) 0 37 (8%) 1 (<1%) 0
Tinnitus 86 (19%) 2 (<1%) 0 71 (16%) 0 0
Liver toxicity 20 (4%) 0 0 33 (7%) 2 (<1%) 0
Alopecia 84 (19%) 0 0 314 (71%) 0 0
Other toxicity 274 (61%) 36 (8%) 3 (1%) 300 (68%) 60 (14%) 7 (2%)
Data are n (%). *Two patients in each group did not receive any chemotherapy, and another three patients in each group 
did not provide any toxicity data. If some toxicity data were provided, any missing toxicity data at that cycle are assumed 
to indicate that toxicity did not occur. One patient in the epirubicin, cisplatin, and capecitabine group died of 
cerebrovascular incident (reported as other toxicity).
Table 4: Chemotherapy toxicity
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p=0·0070). The proportions of patients who achieved R0, 
R1, and R2 were similar in both groups.
No statistically and clinically relevant differences were 
seen between the treatment groups in terms of HRQL 
(appendix pp 8–10) in any of the prespecified domains 
(global quality of life, pain, reflux, appetite loss, or 
dysphagia) or at nearly all timepoints (preoperatively and 3, 
12, and 24 months postoperatively). Global HRQL was 
lower preoperatively during chemotherapy and post-
operatively, and remained lower than at randomisation 
throughout the trial. Appetite loss improved during chemo-
therapy, worsened postoperatively, before returning to 
preoperative levels at 12 months after surgery. Dysphagia 
improved during the trial, and was slightly better at the 
preoperative assessment in the ECX group (appendix p 10) 
than in the CF group. Few changes were seen in pain and 
reflux scores throughout the study. Scores at 24 months 
were mostly within ten points of baseline values within the 
five prespecified domains of HRQL. One exception was 
dysphagia, in which a mean improvement of 10·5 points 
(SD 25·65) was seen in the ECX group at 24 months after 
surgery. The proportion of surviving patients who 
completed HRQL assessments declined over time, 
with 725 (84%) of 860 patients completing an assessment at 
randomisation, 339 (57%) of 595 at 3 months after surgery, 
208 (45%) of 467 at 12 months, and 142 (44%) of 322 at 
24 months.
When the trial and analyses were planned, we felt that 
Mandard TRG 1, 2, or 3 was the most suitable definition 
of good response to treatment. Exploratory analyses 
(appendix p 14) in patients who had available specimens 
suggested that postoperative survival of patients with 
tumours considered to be Mandard TRG 1 or 2 was 
significantly different (appendix p 14) to survival in those 
with tumours considered to be Mandard TRG 3, 4, or 5, 
so Mandard TRG 1 or 2 appeared to denote significant 
tumour regression. Applying this definition to the locally 
collected histopathological data, 18 (6%) of 288 patients 
in the CF group and 48 (17%) of 289 patients in the ECX 
group achieved significant tumour regression 
(p<0·0001). Similarly, using the central review data, 
12 (4%) of 339 patients in the CF group and 37 (12%) 
of 317 patients in the ECX group achieved notable 
tumour regression (p<0·0001).
In the exploratory analysis of progression-free survival, 
median progression-free survival (343 events in the 
CF group vs 313 in the ECX group; appendix p 13) was 
Cisplatin and 
fluorouracil 
(n=387)*
Epirubicin, 
cisplatin, and 
capecitabine 
(n=364)*
Type of tumour
Squamous 5/386 (1%) 1/360 (<1%)
Adenocarcinoma 370/386 (96%) 336/360 (93%)
Other 11/386 (3%) 23/360 (6%)
Differentiation
Well 25/379 (7%) 28/336 (8%)
Moderate 167/379 (44%) 158/336 (47%)
Poor 187/379 (49%) 150/336 (45%)
Mandard tumour regression grade (local pathology assessment)
1: Complete regression 9/288 (3%) 32/289 (11%)
2: Mainly fibrosis 9/288 (3%) 16/289 (6%)
3: Increased residual cancer cells 26/288 (7%) 45/289 (16%)
4: Residual cancer cells outgrowing 
fibrosis
104/288 (9%) 97/289 (34%)
5: Absence of regressive changes 140/288 (49%) 99/289 (34%)
Mandard tumour regression grade (central pathology review)
1: Complete regression 5/339 (1%) 21/317 (7%)
2: Mainly fibrosis 7/339 (2%) 16/317 (5%)
3: Increased residual cancer cells 28/339 (8%) 54/317 (17%)
4: Residual cancer cells outgrowing 
fibrosis
194/339 (57%) 164/317 (52%)
5: Absence of regressive changes 105/339 (31%) 62/317 (20%)
Complete resection at all margins
No 143/379 (38%) 108/357 (30%)
Yes 236/379 (62%) 249/357 (70%)
Staging ypT
0 6/383 (2%) 19/359 (5%)
1 28/383 (7%) 49/359 (14%)
2 67/383 (17%) 58/359 (16%)
3 270/383 (70%) 223/359 (62%)
4 12/383 (3%) 10/359 (3%)
(Table 5 continues in next column)
Cisplatin and 
fluorouracil 
(n=387)*
Epirubicin, 
cisplatin, and 
capecitabine 
(n=364)*
(Continued from previous column)
Staging ypN
0 115/385 (30%) 142/361 (39%)
1 232/385 (60%) 191/361 (53%)
2 28/385 (7%) 19/361 (5%)
3 10/385 (3%) 9/361 (2%)
Staging ypM
0 80/378 (21%) 90/356 (25%)
1 22/378 (6%) 13/356 (4%)
X 276/378 (73%) 253/356 (71%)
Extent of resection
R0: absolute curative 212/357 (59%) 223/336 (66%)
R1: relative curative 130/357 (36%) 103/336 (31%)
R2: non-curative 15/357 (4%) 10/336 (3%)
Data are n/N (%). Denominators are total specimens in which the parameter could 
be assessed and results were not missing. ypT=pathological T-stage. 
ypN=pathological N-stage. ypM=pathological M-stage. R0=no tumour cells 
within 1 mm of any resection margin. R1=presence of tumour cells at or within 
1 mm of a longitudinal or radial or circumferential resection margin. 
R2=macroscopically visible tumour left behind during surgery. *Total number of 
patients for whom specimens were obtained.
Table 5: Pathology details
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18·4 months (95% CI 15·2–20·5) in the CF group and 
21·4 months (19·4–24·0) in the ECX group, with an 
HR of 0·84 (95% CI 0·72–0·98, p=0·033). The 
contributing progression-free survival event was either 
local recurrence (60 [17%] of 343 patients in the CF group 
vs 46 [15%] of 313 in the ECX group), distant metastases 
(94 [27%] of 343 people vs 78 [25%] of 313), local recurrence 
and distant metastases (87 [25%] of 343 vs 59 [19%] of 313), 
or death without confirmed progression (102 [30%] 
of 343 vs 130 [42%] of 313).
An exploratory analysis highlighted that the overall 
survival HR did not remain constant over time, and a 
strong interaction with year of randomisation was seen 
(p=0·0004; appendix p 12). Patients randomly assigned 
early in the trial (2005–07) had some survival benefit in 
the ECX group compared with those in the CF group, 
whereas those assigned in later years (2008 onwards) did 
not. The use of PET scans increased greatly over the 
course of the trial, and so a further exploratory subgroup 
analysis was done looking at the effect of receiving a PET 
scan. This subgroup analysis also showed a strong 
interaction with treatment group (p value=0·0008). 
Patients who did not have a PET scan had longer overall 
survival in the ECX group, whereas for patients who did 
receive a PET scan, ECX gave no survival advantage.
Discussion
This study showed that more intensive neoadjuvant 
chemotherapy with four cycles of ECX provided no overall 
or disease-free survival advantage over two cycles of CF in 
897 patients with oesophageal adenocarcinoma. Chemo-
therapy toxicity and serious adverse events were reported 
more often with ECX—as can be expected from four 
cycles of a triplet regimen compared with two cycles of a 
doublet regimen. These adverse events contributed to a 
greater number of patients completing their planned 
chemotherapy and undergoing surgery in the CF group 
than in the ECX group, although surgical resection, 
postoperative complications, and postoperative mortality 
were similar between the groups. In a post-hoc exploratory 
analysis, improved progression-free survival was shown 
with ECX treatment compared with CF treatment.
More patients in the ECX group had a good pathological 
response to chemotherapy (Mandard TRG 1 or 2), and 
consequently more were staged as ypT0 or 1 or ypN0 after 
surgery, than were those in the CF group. Results from 
the MRC gastro-oesophageal ST0338 study showed that 
Mandard TRG 1 or 2 after chemotherapy was associated 
with improved survival compared with Mandard TRG 3, 
4, or 5. Similar exploratory analyses based on response 
to chemotherapy within this study also suggest a 
postoperative survival benefit for those patients with 
Mandard TRG 1 or 2. However, the absolute numbers of 
specimens assessed that were classified as Mandard 
TRG 1 or 2 (48 [17%] of 289 in the ECX group vs 18 [6%] 
of 288 in the CF group) were low, and so this difference 
did not translate into an overall survival benefit.
The results of this trial raise the question of the optimal 
number of preoperative chemotherapy cycles. In the 
absence of a good pathological response of the tumour, 
giving more than two cycles might unnecessarily delay 
surgery. In the current absence of a reliable biomarker 
that enables prediction of responses either before or 
midway through preoperative treatment, the extent of 
preoperative chemotherapy relies on the judgement of the 
clinician after discussion with the patient, to balance the 
possibility of achieving a good response against the risk of 
not being able to proceed to surgery. The results from our 
OE05 trial favour the use of two cycles of a chemotherapy 
doublet if preoperative chemotherapy alone is offered. 
However, two cycles of CF preoperatively has not been 
directly compared with the perioperative approach 
assessed in the MAGIC trial,25 which studied three cycles 
of ECX given preoperatively and post operatively. The 
FFCD-FNCLCC 9703 trial22 also showed the superiority of 
perioperative chemotherapy over surgery alone, using the 
CF regimen in a population predominantly of patients 
with adenocarcinoma. Given the increased proportion of 
patients who achieved a response with ECX treatment in 
our study, a smaller number of preoperative cycles (two 
or three) with a triplet regimen combined with the 
selective use of postoperative chemotherapy for 
responding patients might be a better approach than 
either four cycles of ECX or two cycles of CF.
OE05 showed an improvement in overall survival of 
patients in the CF group (recruited 2005–11) compared 
with the same regimen in OE02 (recruited 1992–98), in 
which the median survival was 1·4 years compared with 
2·0 years in OE05.
A number of potential factors could explain why the 
survival of patients with oesophageal cancer who were 
treated with CF improved with time. Changes in referral 
patterns, moves towards centralisation of surgical services, 
the introduction of endoscopic ultrasonography, and the 
development of multidisciplinary teams are all events that 
occurred towards the end of recruitment to the OE02 
study, and these changes might have led to better patient 
selection for attempted curative treatment by the time of 
this OE05 study. The introduction of routine PET scanning 
might also be an important factor for the absence of 
survival difference in this study. Post-hoc analyses 
indicated that ECX offered a survival benefit in the early 
years of the study when PET scans were rarely used, but 
offered no benefit during the later years when PET was 
used for nearly all patients. ECX might be more effective 
in treating small-volume, disseminated disease that was 
often missed before the routine use of PET scans. Patients 
with this type of disease are now usually identified and 
would have been ineligible for participation in the study.
Neoadjuvant chemoradiotherapy has also led to 
improved survival compared with surgery alone for 
patients with oesophageal adenocarcinoma and squamous 
cell cancers, with a median survival of 48·6 months (95% 
CI 32·1–65·1) with adjuvant therapy compared with 
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24·0 months (95% CI 14·2–33·7) with surgery alone in the 
CROSS trial.39 The HRs for comparison with surgery alone 
are similar with chemoradiotherapy in CROSS (0·73 [95% 
CI 0·55–0·88] in patients with adeno carcinoma) and with 
chemotherapy in MAGIC (0·75 [0·60–0·93]), suggesting 
that although the trials studied slightly different 
populations, the size of benefit might be similar. Trials 
comparing these two approaches directly20,23,24 have shown 
an increased response with chemo radiotherapy, but 
without any subsequent improvement in overall survival.
The present study has a number of advantages over 
other oesophageal cancer trials. This study was confined 
to patients with adenocarcinomas of the oesophagus and 
gastro-oesophageal junction (Siewert type 1 and 2), 
specifically excluding squamous cell cancers and Siewert 
type 3 (gastric cancer). The study involved a large number 
of centres with a detailed protocol regarding pretreatment 
staging, the delivery of chemotherapy and surgery, and 
histopathological assessment. To our knowledge, our 
study is the only prospective randomised trial in neo-
adjuvant treatment and surgery for oesophageal cancer to 
have included a comprehensive prospective assessment of 
HRQL using validated generic and specific measures. 
Although no differences between trial groups were 
observed in HRQL, the data confirm findings from 
much smaller cohort studies.40 Neoadjuvant chemotherapy 
and surgery are associated with reduced HRQL that 
persists for more than 6 months after surgery, and some 
features such as appetite loss persist for at least 12 months. 
These HRQL results should be accepted as the standard 
that can be achieved with current platinum-based or 
fluoropyrimidine-based neoadjuvant chemotherapy and 
surgery, and communicated to patients during shared 
decision making before surgery, along with the likely 
median survival data of the combined interventions. 
Limitations of this study include the changing use of PET 
scanning through the course of this trial as we have 
discussed and its potential effect on the prognosis of 
patients who entered the trial over time. Additional 
limitations are the fact that postoperative chemotherapy 
was not assessed, and the challenge of interpreting and 
implementing these results in the face of the evolving role 
of chemoradiation in the management of oesophagogastric 
adenocarcinomas.
Data published in 2017 show a survival advantage for 
patients treated with docetaxel, oxaliplatin, and 
fluorouracil compared with epirubicin, cisplatin, and 
fluorouracil or ECX given perioperatively for junctional 
and gastric tumours, with a 3-year overall survival of 57% 
for the docetaxel-containing regimen compared with 48% 
with epirubicin, cisplatin, and fluorouracil or ECX (HR 
0·77, 95% CI 0·63–0·94).41 Though an improvement in 
overall survival for biomarker-unselected patients, these 
results highlight that further improvements in outcomes 
are still needed for these patients. Alternative neoadjuvant 
approaches such as chemoradiation are also being 
investigated.42,43 Additional correlative science projects are 
planned for this trial with the aim of identifying subsets of 
patients who might specifically benefit from ECX 
neoadjuvant chemotherapy.
Contributors
DA and DC were joint chief investigators. DA, DC, REL, and SS designed 
the trial and wrote the protocol. DA, DC, MN, JMB, SMG, AC, HIG, AO, 
CR, SS, and REL were the trial management group. DA, DC, JMB, SMG, 
AC, RK, FC, JT, and SF recruited and treated trial patients. CR coordinated 
the trial at the MRC Clinical Trials Unit (CTU) at University College 
London (UCL; London, UK). MN and SS were the trial statisticians. 
DA, DC, MN, and REL drafted the manuscript. MN had access to the raw 
data, analysed the data and constructed the figures. HIG, RL, and SP did 
the central pathology review. All authors were involved in data 
interpretation, manuscript review, and approval of the final manuscript.
Declaration of interests
DC reports grants from Amgen, AstraZeneca, Bayer, Celgene, Merrimack, 
Medimmune, Merck Serono, Sanofi, and The National Institute of Health 
Biomedical Centre at the Institute of Research and Royal Marsden Hospital. 
MN, HIG, and REL report grants from Cancer Research UK (CRUK). SP 
received personal fees from CRUK. JMB receives funding from the Medical 
Research Council ConDuCT-II Hub for Trials Methodology Research at the 
University of Bristol. CR reports grants from CRUK and non-financial 
support from Roche. FC declares personal fees from Servier and Celgene. 
All other authors declare no competing interests.
Acknowledgments
The study was supported by the MRC CTU at UCL, and funded by 
Cancer Research UK (CRUK; grant numbers C1495/A3005 and 
C26441/A16251). CRUK also provided funding for blood, tissue, and 
slide collection, slide scanning, and pathological review. The sponsor 
was the MRC, and the trial was done and analysed at the MRC CTU at 
UCL. We thank all patients and their families for their participation. 
We also thank the investigators and research staff at the trial centres and 
the MRC CTU at UCL, and the members of the Independent Data 
Monitoring Committee and the Independent Trial Steering Committee 
listed on page one of the appendix.
References
1 Sjoquist KM, Burmeister BH, Smithers BM, et al, for the 
Australasian Gastro-Intestinal Trials Group. Survival after 
neoadjuvant chemotherapy or chemoradiotherapy for resectable 
oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 
2011; 12: 681–92.
2 Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. 
Preoperative chemo(radio)therapy versus primary surgery for 
gastroesophageal adenocarcinoma: systematic review with 
meta-analysis combining individual patient and aggregate data. 
Eur J Cancer 2013; 49: 3149–58.
3 Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy 
prolongs survival in operable esophageal carcinoma: a randomized, 
multicenter study of pre-operative radiotherapy and chemotherapy. 
The second Scandinavian trial in esophageal cancer. World J Surg 
1992; 16: 1104–10.
4 Apinop C, Puttisak P, Preecha N. A prospective study of combined 
therapy in esophageal cancer. Hepatogastroenterology 1994; 
41: 391–93.
5 Le Prise E, Etienne PL, Meunier B, et al. A randomized study of 
chemotherapy, radiation therapy, and surgery versus surgery for 
localized squamous cell carcinoma of the esophagus. Cancer 1994; 
73: 1779–84.
6 Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, 
Strawderman M. Randomized trial of preoperative chemoradiation 
versus surgery alone in patients with locoregional esophageal 
carcinoma. J Clin Oncol 2001; 19: 305–13.
7 Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy 
followed by surgery compared with surgery alone in squamous-cell 
cancer of the esophagus. N Engl J Med 1997; 337: 161–67.
8 Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, 
Steinberg S. Randomized clinical trial of preoperative and 
postoperative adjuvant chemotherapy with cisplatin, vindesine, and 
bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 
1988; 96: 242–48.
Articles
12 www.thelancet.com/oncology   Published online August 4, 2017   http://dx.doi.org/10.1016/S1470-2045(17)30447-3
9 Schlag PM. Randomized trial of preoperative chemotherapy for 
squamous cell cancer of the esophagus. The Chirurgische 
Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft 
Fuer Chirurgie Study Group. Arch Surg 1992; 127: 1446–50.
10 Maipang T, Vasinanukorn P, Petpichetchian C, et al. 
Induction chemotherapy in the treatment of patients with 
carcinoma of the esophagus. J Surg Oncol 1994; 56: 191–97.
11 Law S, Fok M, Chow S, Chu KM, Wong J. 
Preoperative chemotherapy versus surgical therapy alone for 
squamous cell carcinoma of the esophagus: a prospective 
randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210–17.
12 Boonstra JJ, Kok TC, Wijnhoven BP, et al. Chemotherapy followed 
by surgery versus surgery alone in patients with resectable 
oesophageal squamous cell carcinoma: long-term results of a 
randomized controlled trial. BMC Cancer 2011; 11: 181.
13 Ancona E, Ruol A, Santi S, et al. Only pathologic complete response 
to neoadjuvant chemotherapy improves significantly the long term 
survival of patients with resectable esophageal squamous cell 
carcinoma: final report of a randomized, controlled trial of 
preoperative chemotherapy versus surgery alone. Cancer 2001; 
91: 2165–74.
14 Burmeister BH, Smithers BM, Gebski V, et al, for the Trans-Tasman 
Radiation Oncology Group (TROG) and the Australasian 
Gastro-Intestinal Trials Group (AGITG). Surgery alone versus 
chemoradiotherapy followed by surgery for resectable cancer of the 
oesophagus: a randomised controlled phase III trial. Lancet Oncol 
2005; 6: 659–68.
15 Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of 
trimodality therapy with cisplatin, fluorouracil, radiotherapy, and 
surgery compared with surgery alone for esophageal cancer: 
CALGB 9781. J Clin Oncol 2008; 26: 1086–92.
16 Mariette C, Dahan L, Mornex F, et al. Surgery alone versus 
chemoradiotherapy followed by surgery for stage I and II 
esophageal cancer: final analysis of randomized controlled phase III 
trial FFCD 9901. J Clin Oncol 2014; 32: 2416–22.
17 van Hagen P, Hulshof MC, van Lanschot JJ, et al, for the CROSS 
Group. Preoperative chemoradiotherapy for esophageal or 
junctional cancer. N Engl J Med 2012; 366: 2074–84.
18 Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of 
RTOG trial 8911 (USA Intergroup 113): a random assignment trial 
comparison of chemotherapy followed by surgery compared with 
surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719–25.
19 Medical Research Council Oesophageal Cancer Working Group. 
Surgical resection with or without preoperative chemotherapy in 
oesophageal cancer: a randomised controlled trial. Lancet 2002; 
359: 1727–33.
20 Klevebro F, Alexandersson von Döbeln G, Wang N, et al. 
A randomized clinical trial of neoadjuvant chemotherapy versus 
neoadjuvant chemoradiotherapy for cancer of the oesophagus or 
gastro-oesophageal junction. Ann Oncol 2016; 27: 660–67.
21 Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, 
Hennessy TP. A comparison of multimodal therapy and surgery for 
esophageal adenocarcinoma. N Engl J Med 1996; 335: 462–67.
22 Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy 
compared with surgery alone for resectable gastroesophageal 
adenocarcinoma: an FNCLCC and FFCD multicenter phase III 
trial. J Clin Oncol 2011; 29: 1715–21.
23 Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of 
preoperative chemotherapy compared with chemoradiotherapy in 
patients with locally advanced adenocarcinoma of the 
esophagogastric junction. J Clin Oncol 2009; 27: 851–56.
24 Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent 
radiation therapy required in patients receiving preoperative 
chemotherapy for adenocarcinoma of the oesophagus? 
A randomised phase II trial. Eur J Cancer 2011; 47: 354–60.
25 Cunningham D, Allum WH, Stenning SP, et al. 
Perioperative chemotherapy versus surgery alone for resectable 
gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.
26 Twelves C, on behalf of the Xeloda Colorectal Cancer Group. 
Capecitabine as first-line treatment in colorectal cancer. Pooled data 
from two large, phase III trials. Eur J Cancer 2002; 
38 (suppl 2): 15–20.
27 Cunningham D, Starling N, Rao S, et al, for the Upper 
Gastrointestinal Clinical Studies Group of the National Cancer 
Research Institute of the United Kingdom. Capecitabine and 
oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 
358: 36–46.
28 Sobin LH, Wittekind Ch. TNM classification of malignant tumours, 
6th edn. Hoboken, NJ: John Wiley & Sons, 2002.
29 National Cancer Institute. Common terminology criteria for adverse 
events v3.0 (CTCAE). Aug 9, 2006. http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/ctcaev3.pdf 
(accessed Feb 17, 2016).
30 Mapstone N. Data set for the histopathological reporting of 
oesophageal carcinoma (2nd edition). London: Royal College of 
Pathologists, 2007. https://www.rcpath.org/resourceLibrary/
g006oesophagealdatasetfinalfeb07-pdf.html (accessed Oct 28, 2015).
31 Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment 
of tumor regression after preoperative chemoradiotherapy of 
esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 
73: 2680–86.
32 Karamitopoulou E, Thies S, Zlobec I, et al. Assessment of tumor 
regression of esophageal adenocarcinomas after neoadjuvant 
chemotherapy: comparison of 2 commonly used scoring 
approaches. Am J Surg Pathol 2014; 38: 1551–56.
33 Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and 
grading of regression in gastric carcinoma treated with neoadjuvant 
chemotherapy. Cancer 2003; 98: 1521–30.
34 Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: 
a quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993; 85: 365–76.
35 Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and 
psychometric validation of an EORTC questionnaire module, 
the EORTC QLQ-OES18, to assess quality of life in patients with 
oesophageal cancer. Eur J Cancer 2003; 39: 1384–94.
36 Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor 
response and other comparisons of time-to-event by outcome 
variables. J Clin Oncol 2008; 26: 3913–15.
37 Royston P, Parmar MK. Flexible parametric proportional-hazards 
and proportional-odds models for censored survival data, with 
application to prognostic modelling and estimation of treatment 
effects. Stat Med 2002; 21: 2175–97.
38 Cunningham D, Smyth E, Stenning S, et al. Peri-operative 
chemotherapy ± bevacizumab for resectable gastro-oesophageal 
adenocarcinoma: Results from the UK Medical Research Council 
randomised ST03 trial (ISRCTN 46020948). Eur J Cancer 2015; 
51 (suppl 3): S400 (abstr 2201).
39 Shapiro J, van Lanschot JJ, Hulshof MC, et al, CROSS Study Group. 
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone 
for oesophageal or junctional cancer (CROSS): long-term results of 
a randomised controlled trial. Lancet Oncol 2015; 16: 1090–98.
40 Jacobs M, Macefield RC, Elbers RG, et al. Meta-analysis shows 
clinically relevant and long-lasting deterioration in health-related 
quality of life after esophageal cancer surgery. Qual Life Res 2014; 
23: 1155–76.
41 Al-Batran SE, Homann N, Schmalenberg H, et al. Perioperative 
chemotherapy with docetaxel, oxaliplatin, and fluorouracil/
leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or 
capecitabine (ECF/ECX) for resectable gastric or gastroesophageal 
junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, 
randomized phase 3 trial. Proc Am Soc Clin Oncol 2017; 
35: (abstr) 4004.
42 Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised 
phase III trial of perioperative ECF chemotherapy versus 
preoperative chemoradiation plus perioperative ECF chemotherapy 
for resectable gastric cancer (an international, intergroup trial of the 
AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 2015; 15: 532.
43 Keegan N, Keane F, Cuffe S, et al. ICORG 10–14: Neo-AEGIS: 
a randomized clinical trial of neoadjuvant and adjuvant 
chemotherapy (modified MAGIC regimen) versus neoadjuvant 
chemoradiation (CROSS protocol) in adenocarcinoma of the 
esophagus and esophagogastric junction. Proc Am Soc Clin Oncol 
2014; 32: (abstr) TPS4145.
